Mervyn Israel

Mervyn Israel

UNVERIFIED PROFILE

Are you Mervyn Israel?   Register this Author

Register author
Mervyn Israel

Mervyn Israel

Publications by authors named "Mervyn Israel"

Are you Mervyn Israel?   Register this Author

7Publications

55Reads

24Profile Views

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.

Int J Nanomedicine 2012 22;7:975-83. Epub 2012 Feb 22.

Department of Molecular Biology/Immunology, University of North TexasHealth Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX 76107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S28029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289451PMC
June 2012

N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.

J Pharmacol Exp Ther 2007 Nov 10;323(2):658-64. Epub 2007 Aug 10.

Department of Pharmacology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.107.126110DOI Listing
November 2007

Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines.

Mol Pharmacol 2004 Apr;65(4):1038-47

Department of Pharmacology, Center for Anticancer Drug Research, University of Tennessee Cancer Institute, University of Tennessee College of Medicine, Memphis, Tennessee 38163, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.65.4.1038DOI Listing
April 2004

Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis.

Mol Cancer Ther 2002 May;1(7):469-81

Department of Pharmacology, The University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.

View Article

Download full-text PDF

Source
May 2002